Holen Sie sich die Stockscreener-App
0.177
1.61%
-0.0029
Handel nachbörslich:
.19
0.013
+7.34%
Schlusskurs vom Vortag:
$0.1799
Offen:
$0.178
24-Stunden-Volumen:
1.77M
Relative Volume:
1.21
Marktkapitalisierung:
$17.29M
Einnahmen:
$27.47M
Nettoeinkommen (Verlust:
$-26.60M
KGV:
-0.5648
EPS:
-0.3134
Netto-Cashflow:
$-21.86M
1W Leistung:
-21.68%
1M Leistung:
-40.96%
6M Leistung:
-75.67%
1J Leistung:
-73.78%
1-Tages-Spanne:
$0.1657
$0.1894
1-Wochen-Bereich:
$0.1657
$0.2335
52-Wochen-Spanne:
$0.1657
$1.03
Cue Biopharma Inc Stock (CUE) Company Profile
Firmenname
Cue Biopharma Inc
Sektor
Branche
Telefon
617-949-2680
Adresse
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.177 | 17.57M | 27.47M | -26.60M | -21.86M | -0.3134 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-13 | Eingeleitet | Jefferies | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-11-21 | Eingeleitet | Piper Sandler | Overweight |
| 2022-01-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-03 | Eingeleitet | Craig Hallum | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-04-09 | Eingeleitet | Stifel | Buy |
| 2020-01-28 | Eingeleitet | BTIG Research | Buy |
| 2020-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten
CUE Should I Buy - Intellectia AI
CUE.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CUE.O PE Ratio & Valuation, Is CUE.O Overvalued - Intellectia AI
CUE News & Events - Intellectia AI
CUE.O Forecast — Price Prediction for 2026. Should I Buy CUE.O? - Intellectia AI
CUE.O Technical Analysis & Stock Price Forecast - Intellectia AI
[EFFECT] Cue Biopharma, Inc. SEC Filing - stocktitan.net
IPO Launch: Is Cue Biopharma Inc benefiting from interest rate changesWeekly Market Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Cue Biopharma names Lucinda Warren interim CEO By Investing.com - Investing.com Australia
CUE stock slips as CEO leaves after just six months in role - MSN
Cue Biopharma CEO Resignation Leads to 8% Stock Drop - Intellectia AI
Cue Biopharma Appoints CFO Dr. Kerri-Ann Millar as Interim CEO Following Daniel Passeri’s Departure - geneonline.com
Cue Biopharma Names Lucinda Warren Interim Chief Executive - TipRanks
Cue Biopharma names Lucinda Warren interim CEO - investing.com
Cue Biopharma IncLucinda Warren to continue as chief financial and business officerSEC filing - marketscreener.com
Cue Biopharma Appoints Lucinda Warren as Interim President and CEO Following Leadership Transition - Quiver Quantitative
Cue Biopharma Announces CEO Transition - weeklyvoice.com
Leadership shift at Cue Biopharma (NASDAQ: CUE) as Warren steps up - Stock Titan
Movement Recap: Is Cue Biopharma Inc forming a bullish divergence2026 Action & High Conviction Investment Ideas - baoquankhu1.vn
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026 - Bluefield Daily Telegraph
Cue Biopharma Inc stock faces key test amid biotech volatility and pipeline progress - AD HOC NEWS
Cue Biopharma (CUE) Projected to Post Earnings on Monday - Defense World
If You Invested $1,000 in Cue Biopharma Inc (CUE) - Stock Titan
Published on: 2026-03-21 13:01:47 - baoquankhu1.vn
Buyout Rumor: What chart patterns are forming on Cue Biopharma IncShare Buyback & Community Consensus Picks - baoquankhu1.vn
Certain Stock Incentive Plan of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 20-MAR-2026. - marketscreener.com
Certain Common Stock of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 20-MAR-2026. - MarketScreener
Certain Options of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 20-MAR-2026. - marketscreener.com
Loss Report: Can Cue Biopharma Inc outperform in the next rallyIndex Update & Verified Momentum Stock Alerts - baoquankhu1.vn
Cue Biopharma (NASDAQ: CUE) files $300M shelf registration, $12.7M ATM via Jefferies - Stock Titan
Cue Biopharma 2024 Annual Report – Clinical-Stage Immunotherapy Pipeline, Regulatory Strategy, and Collaboration Highlights - Minichart
CUE SEC FilingsCue Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Stock Report: Whats the RSI of Cue Biopharma Inc stockEarnings Growth Report & Smart Money Movement Alerts - baoquankhu1.vn
Cue Biopharma earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Bitget
Cue Biopharma issues quarterly and annual earnings update - Traders Union
Cue Biopharma : Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - marketscreener.com
Reverse split on agenda as Cue Biopharma (CUE) plans 2026 virtual meeting - Stock Titan
Cue Biopharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Cue Biopharma (CUE) posts 2025 results and $15M ImmunoScape pact - Stock Titan
Cue Biopharma (CUE) pivots to autoimmune focus amid going concern risk - Stock Titan
Cue Biopharma, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Cue Biopharma (CUE) price target decreased by 20.00% to 4.08 - MSN
Published on: 2026-03-13 09:51:08 - baoquankhu1.vn
Cue Biopharma (CUE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Cue Biopharma to present new in vitro data for CUE-401 - TipRanks
Cue Biopharma (CUE) Unveils Promising CUE-401 Data at Global Con - GuruFocus
Cue Biopharma unveils in vitro data for CUE-401 in autoimmune disease research - Traders Union
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - The Manila Times
CUE-401 lab data hint at rebalancing immune attacks in autoimmune disease - stocktitan.net
Bull Run: Can Cue Biopharma Inc disrupt its industryWeekly Profit Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Finanzdaten der Cue Biopharma Inc-Aktie (CUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):